B. Riley Securities Reiterates Buy on OptimizeRx, Lowers Price Target to $11
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
B. Riley Securities analyst Anderson Schock reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $28 to $11.
B. Riley Securities analyst Anderson Schock reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $28 to $11.